Propanc Biopharma Inc (PPCB) News & EventsPPCBNews & EventsPropanc Biopharma Inc

Propanc Biopharma Announces New Data for Pancreatic Cancer

Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic ductal adenocarcinoma, or PDAC. In orthotopic and patient-derived xenograft models of advanced PDAC, three-times-weekly intravenous PRP achieved: greater than 90%, mean, tumor growth inhibition versus vehicle controls; marked reduction in metastatic burden in the liver and peritoneum; significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition markers; enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved efficacy and median overall survival extension of more than 2.5-fold in treated animals compared with controls. These results were built on previously reported greater than 85% tumor growth inhibition data and peer-reviewed findings on PRP's effects on PDAC fibroblasts. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients with a favorable safety profile and no severe treatment-related adverse events.

Propanc Biopharma Compares PRP with Competitor Therapies

Propanc Biopharma provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines and Erasca. The company articulates why PRP's mechanism, promoting cancer cell differentiation, reversing epithelial-mesenchymal transition, and targeting cancer stem cells via pancreatic proenzymes, positions it as a potential long-term therapy of choice, particularly for aggressive, treatment-resistant cancers such as pancreatic ductal adenocarcinoma. PRP is a proprietary fixed-ratio combination of pancreatic proenzymes trypsinogen and chymotrypsinogen, administered once weekly by intravenous injection. PRP holds FDA Orphan Drug Designation for pancreatic cancer. The company is advancing toward a Phase 1b first-in-human study in up to 40-45 patients with advanced solid tumors, with GMP manufacturing and clinical partnerships progressing in 2026. The company expects to file a clinical trial application for the Phase 1b clinical study in advanced cancer patients in Q4 this year.

Propanc Biopharma Announces New Data for PRP in Pancreatic Cancer

Propanc Biopharma announced new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma, one of the most aggressive and treatment-resistant solid tumors. In orthotopic and patient-derived xenograft models of advanced PDAC, 3 times weekly intravenous PRP achieved: greater than 90% mean tumor growth inhibition versus vehicle controls; marked reduction in metastatic burden in liver and peritoneum; significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition markers; enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, allowing lower chemotherapy doses while improving efficacy and median overall survival extension of more than 2.5-fold in treated animals compared with controls. These results are built on previously reported greater than 85% tumor growth inhibition data and peer-reviewed findings on PRP's impact on PDAC fibroblasts. Translational analyses from limited prior compassionate-use experience with related proenzyme formulations further support a favorable safety profile and signals of prolonged survival in advanced solid-tumor patients.